Tkachev V, Goodell S, Opipari A, Hao L, Franchi L, Glick G, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015;194:5789-800 pubmed publisher

Tsukahara T, Iwase N, Kawakami K, Iwasaki M, Yamamoto C, Ohmine K, et al. The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies. Gene Ther. 2015;22:209-15 pubmed publisher

Wang C, Yi T, Qin L, Maldonado R, von Andrian U, Kulkarni S, et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest. 2013;123:1677-93 pubmed publisher

Singh A, Dey A, Mohan A, Sharma P, Mitra D. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-? producing T cells. PLoS ONE. 2012;7:e44728 pubmed publisher

Rosignoli G, Lim C, Bower M, Gotch F, Imami N. Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. Clin Exp Immunol. 2009;157:90-7 pubmed publisher

Jurado J, Alvarez I, Pasquinelli V, Martinez G, Quiroga M, Abbate E, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol. 2008;181:116-25 pubmed